Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin versus pioglitazone versus other glucose-lowering drugs in type 2 diabetes
IRCT20130610013612N9Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of sitagliptin and pioglitazone in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Tabriz University of Medical Sciences. Primary endpoints: Fibrinogen, Triglycerides and 3 more. Started Apr 2018; status: completed.
02
Drugs
sitagliptinpioglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on IRCT20130610013612N9.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20130610013612N9.